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Sphingolipids are ubiquitous components of cell membranes and their metabolites ceramide (Cer), sphingosine (Sph), and sphingosine-1-
phosphate (S1P) have important physiological functions, including regulation of cell growth and survival. Cer and Sph are associated with growth
arrest and apoptosis. Many stress stimuli increase levels of Cer and Sph, whereas suppression of apoptosis is associated with increased intracellular
levels of S1P. In addition, extracellular/secreted S1P regulates cellular processes by binding to five specific G protein coupled-receptors (GPCRs).
S1P is generated by phosphorylation of Sph catalyzed by two isoforms of sphingosine kinases (SphK), type 1 and type 2, which are critical regulators
of the “sphingolipid rheostat”, producing pro-survival S1P and decreasing levels of pro-apoptotic Sph. Since sphingolipid metabolism is often
dysregulated in many diseases, targeting SphKs is potentially clinically relevant. Here we review the growing recent literature on the regulation and
the roles of SphKs and S1P in apoptosis and diseases.
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De novo synthesis of sphingolipids is initiated at the cyto-
plasmic face of the endoplasmic reticulum (ER) by the
condensation of serine and palmitate to produce 3-keto-sphin-
ganine catalyzed by serine palmitoyl transferase (Fig. 1) [1]. In
two rapid enzymatic reactions, 3-keto-sphinganine is reduced to
sphinganine (dihydro-sphingosine, DHS) by 3-keto-sphinga-
nine reductase in a NADH-dependent reaction. DHS is then N-
acylated by dihydroceramide synthase using various fatty acyl
CoAs to form dihydroceramide (DHCer) which is converted to
Cer by a desaturase. The insertion of the trans 4,5-double bond
into Cer by the desaturase is an important reaction because Cer,
but not DHCer, mediates apoptosis [2]. Cer (and DHCer) is
translocated from the ER to the Golgi apparatus in a non-
vesicular transport manner by CERT [3], a cytoplasmic protein
with a phosphatidylinositol-4-phosphate-binding domain and a
putative catalytic domain for lipid transfer. Once in the Golgi,
Cer and DHCer can be used to form sphingomyelin (SM) and
dihydrosphingomyelin (DH-SM), respectively, by sphingomye-
lin synthase on the lumenal side of the Golgi, or to glucosyl-
ceramide (GlcCer) and dihydroglucosylceramide (DH-GlcCer)
on the cytosolic surface of the Golgi [4]. After translocation into
the Golgi lumen, GlcCers are further converted to lactosylcer-
amides and more complex glycosphingolipids [5]. The
sphingoid base sphingosine (Sph) is not produced de novo
and is only formed from Cer by ceramidase-catalyzed
hydrolysis. Sph can also arise during degradation of plasma
membrane glycosphingolipids and SM in the endocytic
recycling pathway.
Sph and DHS can be phosphorylated by SphKs to form S1P
and dihydro-S1P, which are both substrates for specific S1P
phosphatases that reside in the ER. Yeast SphKs, the products of
two genes, LCB4 and LCB5, are required for the efficient utili-
zation of exogenously added sphingoid bases [6]. LCB4 is prin-
cipally required for this process and is found on the cytoplasmic
face of internal membranes, including the ER, Golgi and pro-
bably endosomes [7]. There are also two mammalian isoforms,
SphK1 and SphK2, that differ in sequence, catalytic properties,
localization, and in their functions [8]. SphK1 has pro-survival
functions and is mainly a cytosolic protein, whereas SphK2 is a
putative BH3-only protein, inhibits cell growth and enhances
apoptosis [9]. Recent results from our lab demonstrated that
SphK1 decreases and SphK2 increases ceramide levels in HEK
293 cells.
From a mechanistic point of view, our results support the
notion that SphK2, similar to yeast LCB4 [10], might play a role
in the sphingosine salvage pathway of mammalian cells, acting
in concert with S1P phosphatase (SPP-1) to convert S1P back tosphingosine and then to ceramide in the ER. Ceramide
generated in the ER has been linked to increased Ca2+ release,
leading to apoptosis. Moreover, cytosolic S1P formed by
SphK1 inhibits de novo ceramide biosynthesis as a cellular
sensing mechanism to minimize unneeded biosynthesis of
ceramide [8]. S1P can also be further degraded by S1P lyase
(SPL), an integral ER membrane protein facing the cytoplasm
[11], which yields the cleavage products, hexadecenal and
ethanolamine phosphate, the major exit route of metabolism of
sphingolipids (Fig. 1).
2. The sphingosine kinase family
SphKs are an evolutionary conserved lipid kinase family
that contains five conserved domains. SphK1 was originally
purified to homogeneity from rat kidney as a 49-kDa protein.
Based on tryptic peptides, murine SphK1 was then cloned [12].
Two isoforms, termed SphK1α and SphK1β, with 42.2 and
43.2 kDa predicted molecular mass were identified which only
differed in a few amino acids at their N-termini, suggesting that
they were derived by alternative splicing. SphK1 has a broad
tissue distribution, with higher levels in brain, heart, lung and
spleen. It has no trans-membrane domains, rather it has three
calcium/calmodulin-binding consensus sequences and several
potential protein kinase phosphorylation sites [12]. Indeed, the
lack of a hydrophobic domain or an identifiable signal peptide
is consistent with its predominant cytosolic localization [12].
SphK1 displays specificity for the natural trans isomer of
D-erythro-sphingosine. Several SphK inhibitors have been
discovered including threo-dihydrosphingosine (DHS), N,
N-dimethylsphingosine (DMS) [13], fungal-derived inhibitors
[14], and 2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole
[15], which have been widely used to implicate SphK and
S1P formation in many biological processes. Yet, most of these
results must be interpreted with caution as all of the known
inhibitors block both SphK1 and SphK2.
Based on homology to SphK1, a second isoform, SphK2,
was cloned and characterized from mouse and human [16].
SphK2 shares five conserved domains with SphK1 (about 80%
similarity and 50% identity) but has an additional 200 amino
acids, making it a predicted 68 kDa protein. SphKs have a
conserved ATP-binding motif (SGDGX(17–21)K(R)) found in
diacylglycerol kinases [16] that has some similarity to the
highly conserved glycine-rich loop involved in binding ATP in
the catalytic site of many protein kinases [17]. Unlike SphK1,
SphK2 has a somewhat lower substrate specificity and also can
phosphorylate FTY720, an immunosuppressive drug currently
in Phase 3 clinical trials for kidney transplantation and multiple
sclerosis treatment [18–20]. Although SphK2 has four
Fig. 1. Scheme showing ceramide biosynthesis and pathways leading to production of S1P. S1P in turn can act either in an autocrine or paracrine manner through five S1P receptors to regulate cellular functions. It may
also have intracellular actions.
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in HEK 293 cells, it is found mainly in the cytosol [16].
However, in MCF-7 breast cancer cells, endogenous SphK2 is
almost exclusively nuclear localized [21], while it is mainly at
the plasma membrane, at lower levels in internal membranes,
and barely detectable in the cytosol of HEK 293 and MDA-MB-
453 breast cancer cells [22].
3. Sphingosine kinases and production of
sphingosine-1-phosphate
SphK is stimulated by numerous external stimuli resulting in
increased intracellular S1P concentration and increased release
from certain cell types. These stimuli include agonists of growth
factor receptors (including PDGF, VEGF, NGF, and EGF),
ligands for GPCRs, transforming growth factor beta, the pro-
inflammatory cytokine TNF-alpha and cross-linking of immu-
noglobulin receptors (reviewed in [5]). In most cases, the
importance of SphK1 activation and concomitant production of
S1P in the regulation of many biologically responses was only
indirectly inferred by the ability of pan SphK inhibitors to block
agonist-induced effects.
Intracellularly produced S1P can act in autocrine/paracrine
manner to stimulate S1P receptors present at the cell surface
(signaling “inside-out”) and initiate downstream G protein-
mediated signaling, including activation of Src, focal adhesion
kinases and Rac, all important in cell migration (Fig. 1). Inte-
restingly, binding of S1P to S1P1 or S1P3 stimulates chemotaxis
whereas binding to S1P2 generally has a negative effect [23,24].
Some evidence indicates that intracellularly produced S1P
serves as a modulator of calcium responses by a mechanism
primarily dependent on the phospholipase C (PLC)/inositol
1,4,5-triphosphate (InsP3) pathway [25], while S1P-mediated
intracellular calciummobilization is independent of GPCRs [26]
and InsP3 formation [27]. SphK1/S1P also enhances endothelial
cell survival through platelet endothelial cell adhesion molecule-
1-(PECAM-1)-dependent activation of phosphatidylinositol
3-kinase/AKT and regulation of Bcl-2 family members [28].
TNF-α and other cytokines stimulate SphK1 leading to the
activation of the transcription factor nuclear factor-κB (NF-κB)
[29]. A recent study showed that endothelial nitric oxide syn-
thase activation by TNF-α occurs through sequential activation
of neutral sphingomyelinase 2 and SphK1/S1P and depends on
both S1P1 and S1P3 receptors [30]. Activation of SphK1 by
VEGF activates Ras, and, consequently, extracellular signal
regulated kinase (ERK)/mitogen-activated protein kinase
(MAPK) signaling and cell growth [31]. In most of these
reports, activation of SphK1 is transient, reaching a peak within
a few minutes, and declining rapidly thereafter. We recently
showed that EGF activates both endogenous SphK1 and SphK2
[22,32]. This is the first example of agonist-dependent regula-
tion of SphK2 [22]. Treatment with EGF significantly increased
endogenous S1P levels in naïve cells as well as in SphK2-
expressing cells [22], which in turn, led to activation of S1PRs
(“inside-out signaling”), to regulate cell movement towards
EGF. Moreover, in MDA-MB-453 cells, SphK1 and SphK2 had
overlapping and/or complementary functions in regulation ofEGF-induced migration. In contrast, only SphK1, but not
SphK2, was required for migration of mast cells toward antigen
[24] and for C5a receptor-dependent chemotaxis of macro-
phages [33]. Similarly, although downregulation or overexpres-
sion of SphK2 had no effect on migration of HEK 293 cells
toward EGF, in sharp contrast, down-regulation or overexpres-
sion of SphK1 reduced or enhancedmigratory responses of these
cells toward EGF [22].
4. Mechanisms of sphingosine kinase activation
Since SphK1 is mainly present in the cytosol and its
substrate, Sph, is generated in membranes, it is not surprising
that translocation of SphK1 to the plasma membrane appears
to be an important and common feature of its activation [5].
The rapid onset of activation of SphK1 is most consistent
with post-translational modification mechanisms. Of note,
yeast LCB4 is regulated by several types of post-translational
modifications, including phosphorylation, ubiquitination, and
palmitoylation [34,35]. Indeed, the phorbol ester, phorbol 12-
myristate 13-acetate (PMA) induces protein kinase C-
mediated phosphorylation of SphK1 and its translocation to
the plasma membrane, leading to enhanced release of S1P to
the medium which, in turn, triggers autocrine/paracrine
signaling [36]. Another report subsequently showed that
PMA and TNF-α induce phosphorylation of SphK1 at Ser225
catalyzed by ERK2 and cyclin-dependent kinase 2 increasing
its enzymatic activity, which was accompanied by its trans-
location to the plasma membrane [37]. Previous studies had
shown that intracellularly generated S1P acts upstream of
ERK1/2 in the signaling pathways initiated by TNF-α and
VEGF [31,38,39]. Taken together, these results imply that
some level of activation of SphK1 must occur prior to further
activation by ERK kinases [37]. It is possible that the initial
step in such an autocrine activation loop of SphK1 involves
translocation to the cell membrane and/or interaction with
other specific proteins or lipids that regulate its activity. In
this regard, nearly a decade ago, we found that acidic phos-
pholipids, particularly phosphatidylserine, dose-dependently
increase SphK activity, whereas neutral phospholipids have
no effect [40]. These interactions likely have biological
significance since it was later shown that specific interaction
of phosphatidic acid with SphK1 was required for its
translocation to membrane compartments [41]. More recently,
using surface plasmon resonance, Stahelin et al. showed that
SphK1 selectively binds phosphatidylserine over other anionic
phospholipids and that the highly conserved Thr54 and Asn89
residues in the putative membrane binding surface of SphK1
were essential for the lipid selectivity and membrane targeting
both in vivo and in vitro and that S225 phosphorylation
increases the selective membrane binding and lipid–protein
interactions [42].
There is accumulating evidence that the activity and sub-
cellular localization of SphK1 are also influenced by its
interaction with adaptor proteins. SphK1 interacting proteins
comprise a heterogeneous array and include such diverse mole-
cules as RPK118 [43], a protein related to protein kinase A
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and delta-catenin/NPRAP (neural plakophilin-related armadillo
repeat protein) [47]. All of these interactors have been shown to
co-immunoprecipitate with SphK1 but the physiological
significance of their interaction with SphK1 remains unclear.
The important mast cell protein tyrosine kinases Lyn and Syk
were recently identified as SphK1 interacting proteins by an
antibody array method [48]. Although neither Lyn nor Syk
phosphorylated SphK1, direct interaction of SphK1 with Lyn
increased the activity of both kinases [48]. Moreover, this inter-
action results in the recruitment of SphK1 to FcεRI and shortly
after stimulation, in the appearance of both Lyn and SphK1 in
lipid rafts of the cell membrane. In mast cells isolated from Lyn
knockout mice, there was no increase in SphK1 activity after
FcεRI crosslinking, confirming that interaction with Lyn was
required [48].
It has long been known that SphK1 plays an important role in
cell survival and that its activation enhances cell survival in
response to TNF-α [38,49]. SphK1 was subsequently shown to
directly interact with the TNF receptor-associated factor 2
(TRAF2), resulting in activation of SphK1 that is required for
TRAF2-mediated activation of NF-κB, but not for activation of
c-Jun N-terminal kinase [29]. These findings suggest that SphK1
may be a component of the signal transduction pathway
downstream of the TNF receptor and TRAF2.
In some cells, a more sustained increase of SphK activity has
been observed following stimulation, lasting for hours or days,
most likely resulting from increased transcription. Examples
include NGF-induced increases in SphK activity in neuronal
cells [50], PMA effects in HeLa cells [51], vitamin D3 treatment
of HL60 cells [52], and stimulation of fibroblasts with TNF-α
[53]. Thus, it is likely that regulation of SphK1 at the transcrip-
tional level may also have important physiological functions.
Although much less is known of SphK2 interacting proteins,
we found that the pro-apoptotic Bcl-xL protein specifically
interacts with SphK2 [9]. The IL-12 receptor was also identified
as a SphK2 interactor by a yeast two-hybrid approach. This
interaction was linked to IL-12 receptor signaling events [54],
potentially associating SphK2 with Th1 effector functions.
5. Sphingosine kinases, S1P and apoptosis
SphKs and S1P phosphatases (SPPs) are essential cellular
regulators of S1P levels [5]. Many studies in various cell types
have confirmed our original observation that overexpression of
SphK1 and increased S1P production promotes cell growth,
enhances the G1/S transition and increases cells in S-phase [55].
For example, SphK1 overexpression in NIH 3T3 fibroblasts
promotes growth of cells in soft agar and tumor formation in
mice, probably owing to its role in Ras and ERK1/2 signaling,
suggesting a potential oncogenic function [31,56,57]. Consistent
with these observations, a dominant-negative form of SphK1
inhibited estrogen-mediated mitogenic signaling in MCF-7 cells
and decreased their ability to form tumors in nude mice [58].
Furthermore, recently it was shown that phosphorylation of
SphK1 and subsequent membrane translocation is required for
its pro-oncogenic function [59]. Importantly, SphK1 is frequentlyoverexpressed in a variety of solid tumors, suggesting an
important role in human tumorigenesis [15,60]. SphK1 also
mediates VEGF-induced Ras activation in bladder cancer cells
by favoring inactivation of Ras-GAP, thereby promoting
tumorigenic processes [61]. We have shown that decreasing
SphK1 expression with siRNA markedly reduces EGF-
dependent MCF-7 cell growth, while downregulation reduced
the percentage of cells in S and G2/M phases, and increased
cells in G0/G1 phase [32]. Together, these results suggest that
endogenous SphK1 regulates the progression of MCF-7 cells
through the cell cycle. Decreasing SphK1 expression by RNA
interference or inhibiting its activity also significantly
decreased the proliferation of U-1242 MG and U-87 MG
glioblastoma cells [62]. Moreover, this prevented cells from
exiting G1 phase of the cell cycle and marginally increased
apoptosis. Surprisingly, knockdown of SphK2 expression
inhibited glioblastoma cell proliferation more potently than
did SphK1 knockdown. Thus, both SphK isoforms may be
important regulators of glioblastoma cell proliferation.
We previously found that sensitivity of MCF-7 cells to the anti-
cancer drug doxorubicinwas potentiated by the pan SphK inhibitor,
DMS [57]. Relevant to this, an interesting recent finding was that
induction of apoptosis in MCF-7 cells by doxorubicin was
accompanied by degradation of SphK1 [63]. MCF-7 cells are
null for the executioner caspase-3 and depend mainly on caspase-7
for the execution of the cell death program [64]. In agreement, we
found that activation of caspase-7 and cleavage of PARP induced
by doxorubicin inMCF-7 cellswere accelerated by downregulation
of SphK1 [32]. As resistance to anti-cancer drugs is a common
feature in breast cancer therapy, these observations suggest that the
effectiveness of some chemotherapeutic agents might be related to
the level of expression of SphK1.
Our laboratory and others have demonstrated that in contrast
to SphK1, overexpression of SphK2 suppresses growth and
enhances apoptosis, preceded by cytochrome c release and
activation of caspase-3 [9,21]. Moreover, SphK2-induced apop-
tosis was independent of activation of S1P receptors [9]. Se-
quence analysis revealed that SphK2 contains a 9 amino acid
motif similar to that present in Bcl2-homology domain 3 (BH3)-
only proteins, a pro-apoptotic subgroup of the Bcl-2 family. As
with other BH3-only proteins, SphK2 interacted physically with
the anti-apoptotic member Bcl-xL [9]. However, mutation of the
conserved leucine present in all BH3 domains, that is critical for
their ability to induce apoptosis [65], only partially reduced
SphK2-induced apoptosis [9], suggesting that the SphK2 protein
possesses additional determinants important for this function.
Recently, we found that the catalytic activity of SphK2 and its
localization to the ER, where it functions to increase Cer levels,
contribute to its apoptogenic effects [8]. Our results imply that
the cellular location where S1P is produced determines how
SphK1 and SphK2, two closely related enzymes that use the
same substrate and generate the same product, have opposite
effects on cell survival and opposing functions in regulation of
sphingolipid metabolism and thus levels of ceramide [8].
Increases in cytosolic free calcium have been linked to both
survival and apoptosis; while calcium is necessary for cell growth
and survival, its inappropriate increase may also result in cell death
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connected to the ER-calcium apoptotic pathway [68]. The calcium
concentration in the ER ([Ca2+]ER) is an important determinant of
cellular responses to stress [68] and is regulated by the balance
between anti- and pro-apoptotic Bcl-2/BAX family members [69].
Moreover, Cer itself causes the release of calcium from the ER and
thus increases both cytosolic and mitochondrial calcium. The
reduction of [Ca2+]ER or buffering of cytoplasmic calcium changes
can prevent mitochondrial damage and protect cells from Cer-
induced apoptosis [67]. S1P may also contribute to regulation of
calcium homeostasis in mammalian cells, particularly in response
to stress, reminiscent of its function in yeast [70] and plants [71] that
do not have S1P receptors.
Interestingly, a mutant Dictyostelium discoideum slime
mold null for S1P lyase displayed higher viability in
stationary growth phase than the wild-type and were resistant
to the anti-cancer drug cisplatin [72], suggesting a role for
S1P even in this primitive organism [73]. The SphK genes in
D. discoideum – sgkA and sgkB – are homologous to those
of other species and are biochemically equivalent to human
SphK1 and SphK2, respectively. Disruption of sgkA and sgkB
by homologous recombination (both single and double
mutants) or overexpression of the SphK1 analogue resulted
in altered growth rates while the null mutants showed
increased sensitivity to cisplatin, and mutants overexpressing
the SphK2 analogue had increased resistance. The increased
sensitivity of the SphK2-null mutants was reversed by the
addition of S1P, and the increased resistance of SphK1
overexpressors was reversed by DMS suggesting that SphKs
might also be good targets for modulating the sensitivity to
platinum-based anti-cancer drugs [74].
6. S1P regulates ceramide biosynthesis and apoptosis
Apoptotic Cer can be generated by the activation of acidic
or neutral sphingomyelinases in response to numerous
apoptotic stimuli [75]. In one example, it was recently
shown that the acidic sphingomyelinase (ASMase) inhibitor
imipramine or knock out of ASMase inhibited increases in
pro-apoptotic C16-Cer and apoptosis induced by TNF-α [76].
Similarly, decreasing Cer levels by overexpression of neutral
ceramidase inhibited TNF-α-induced apoptosis. Cer is also
increased after induction of the mitochondrial apoptotic
pathway as a result of increased de novo biosynthesis and
leads to downstream activation of caspases and apoptosis
[75]. Moreover, there is convincing evidence that Cer
synthase and serine palmitoyltransferase are activated during
apoptosis in response to certain stimuli [75].
As discussed above, the SPPs are also expressed in the ER
and may indirectly regulate Cer and consequently, apoptosis
[77–79]. An attractive hypothesis is that S1P formed by SphK1
may normally directly or indirectly act as a negative regulator of
serine palmitoyltransferase or Cer synthase [8]. It is intriguing to
speculate that this negative regulation of Cer biosynthesis by
S1P might also be the mechanism for its intracellular pro-sur-
vival effects and its ability to suppress exogenous Cer-mediated
apoptosis.7. Sphingosine kinases, S1P and physiological functions
The role of S1P in various physiological processes is under
intense investigation using pharmacological approaches, includ-
ing treatments with S1P, S1PR agonists or antagonists, or SphK
inhibitors. Some examples are discussed below. To date, in vitro
studies have established: (1) the plasticity and adaptability of
expression of S1P receptors (S1PRs) by cells as a function of
activation, and (2) the role of opposing signals from different
S1P receptors as a mechanism for fine tuning the effects of S1P.
Additionally, the development of knock-out mice for specific
S1P receptors has been a milestone in understanding the physio-
logical functions of S1P.
7.1. Cancer-promoting roles of S1P
Overexpression of SphK1 in NIH 3T3 fibroblasts resulted
in the acquisition of a transformed phenotype and tumor forma-
tion in nude mice, demonstrating the oncogenic potential of this
enzyme [56]. Moreover, S1P promotes estrogen-dependent
tumorigenesis of MCF-7 human breast cancer cells [57] and
stimulates invasiveness of human glioblastoma cells [80]. We
recently showed that endogenous SphK1 regulates motility,
growth, and chemoresistance of MCF-7 cells [32], whereas both
SphK1 and SphK2 are involved in EGF-mediated activation and
migration of MDA-MB-453 breast cancer cells [22]. These
results suggest that SphKs/S1P might be critical for growth,
metastasis and chemoresistance of human breast cancers.
7.2. S1P in vasculogenesis and angiogenesis
S1P promotes endothelial cell growth, thereby promoting
blood vessel formation through interaction with signaling by
VEGF, a pivotal angiogenic growth factor [81]. VEGF stimu-
lated SphK1 in T24 bladder tumor cells, which, in turn mediated
VEGF-induced activation of Ras andMAPKs [61]. In an ex vivo
model of angiogenesis, as well as in in vivo studies, a synergistic
effect of S1P with other angiogenic factors such as bFGF and
stem cell factor was observed on vascular sprouting, prolifera-
tion and tube formation during vasculogenesis and de novo
vascularization [82,83]. Moreover, S1P1 null mice die in utero
between embryonic days 13.5 and 14.5 due to a defect in vas-
cular stabilization [84]. Indeed, Chae et al. documented that
S1P1 receptor expression is also induced in angiogenic vessels
in vivo [85]. Recent elegant studies by Proia and colleagues
utilizing SphK1–SphK2 double knockout mice demonstrated an
essential role for S1P in neural and vascular development [86].
These observations suggests that S1P should be included in a
growing list of signaling molecules, such as VEGF, which
regulate the functionally intertwined pathways of angiogenesis
and neurogenesis [86].
7.3. S1P and atherogenesis
Plasma and serum concentrations of S1P have been estimated
to be between 200 and 900 nM. S1P is mainly distributed in the
lipoprotein fraction, with a rank order of high-density lipo-
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(LDL), lower in very low-density lipoprotein (VLDL), and the
lowest content associated with the albumin fraction [87].
Lipoproteins are therefore the major carriers of circulating
S1P, perhaps protecting it from enzymatic degradation, cell
uptake, and continuous ligation of S1P receptors on cells
exposed to plasma or blood. S1P in serum is mainly released
from stores in activated platelets [88], and when released can
interact with endothelial cells thus playing a role in endothelial
cell migration, proliferation and angiogenesis. It is noteworthy
that other circulating cells, such as erythrocytes, neutrophils and
mononuclear cells have relatively high SphK activity but only
constitutively release small amounts of S1P [89]. HDL-
associated S1P has cytoprotective effects, counteracting ox-
LDL-triggered cytotoxicity, suggesting that it may have anti-
atherogenic properties [90]. Increased permeability of the
endothelium to plasma proteins such as LDL is one of the
initiating steps of atherogenesis and S1P normally functions
through S1P1 and S1P3 receptors to decrease the permeability of
the endothelium, acting through both Rho and Rac [91,92]. In
vascular smooth muscle cells, S1P stimulates DNA synthesis in
association with ERK activation, and may play a central role in
excessive fibroproliferative and inflammatory responses to
vascular injury that are hallmarks of atherosclerosis progression
[93,94]. In addition, platelet-derived S1P may contribute to
chemotaxis of primary hematopoietic stem cells to tissue repair
sites subsequent to myocardial infarction and other diseases
[95]. Evidence for a central role of S1P1 in VSMCmigration was
established by the phenotype of S1P1-deficient mice in which
VSMCs do not migrate properly to surround and reinforce
nascent vessels [84]. Moreover, S1P signaling through endothe-
lial S1P1 protects the vasculature against TNF-α-mediated
monocyte-EC interactions in vivo, suggesting that S1P1 agonists
may be efficacious in atherosclerosis [96].
7.4. S1P in modulation of vascular barrier integrity
Acute lung injury (ALI), acute respiratory distress syn-
drome (ARDS), and multiple organ system failure are common
consequences of pulmonary and systemic insults. The lung
pathologies are characterized by early sequestration of neutro-
phils (polymorphonuclear cells or PMN) in the pulmonary
microvasculature, followed by adhesion and migration [97].
Upon activation of PMN, S1P is rapidly synthesized by SphK,
which, in turn, acts to mediate store-operated calcium entry
[98,99]. Using a rat trauma/hemorrhagic shock model, it has
been demonstrated that pre-shock inhibition of SphK with
DMS decreased PMN activation both in vitro and in vivo
[100]. To investigate the efficacy of S1P as a potential thera-
peutic avenue for vascular barrier dysfunction, experiments
were conducted using isolated perfused murine lung models
and bacterial endotoxin (LPS)-induced ALI in intact animals
[101]. In these studies, intravenous S1P infusion resulted in
rapid and significant reduction of lung weight gain and
significantly reduced microvascular permeability and inflam-
mation, consistent with systemic barrier enhancement. Inte-
restingly, the S1P analog FTY720 also produced profoundbarrier enhancement and reduced lung inflammation [102].
Mechanistically, S1P induces cortical reorganization of the
endothelial cytoskeleton and the distribution, assembly and
stabilization of adherens junctions and focal adhesion com-
plexes on the cell membrane via S1P receptor signaling and
activation of Rac [103].
Activation of the complement system and production of
anaphylatoxin C5a is associated with a variety of pathologies,
including septic shock and ARDS, and in immune complex-
dependent diseases, such as rheumatoid arthritis. C5a regulates
inflammatory functions through its receptor C5aR (CD88) and
increases intracellular calcium, degranulation, cytokine gen-
eration and chemotaxis. Importantly, C5a also stimulates SphK1
and its membrane translocation and generation of S1P and
downregulation of SphK1 suppressed these effects of C5a
[33]. Complementary in vivo data demonstrated that pre-
treating mice with DMS to inhibit SphK1 prior to C5a injec-
tion, prevented C5a-triggered neutropenia, increases in serum
levels of TNF-α and IL-6, as well as neutrophil and monocyte
infiltration [104].
7.5. S1P, inflammation, and immunity
Profound effects of S1P have been described on multiple
aspects of differentiation, survival, migration, tissue homing,
and effector functions of mononuclear phagocytes and T and B
lymphocytes [105]. S1P and its S1P1 receptor control emigration
of thymocytes into the blood and the recirculation and tissue
distribution of T and B cells exerting direct chemotactic effects.
The same ligand/receptor system controls recirculation of naïve
lymphocytes and S1P as well as S1P1 agonists induce down-
regulation of S1P1, altering the tissue distribution of effector
lymphocytes [105]. Activation of T and B lymphocytes by
various immunological stimuli also suppresses expression of
S1P1 and S1P4 with a subsequent significant decrease of recep-
tor-associated signaling [106,107]. The selective effect of S1P
on Tcell recruitment renders S1P a possible mediator to target, in
combination with immunosuppressive agents aiming at T cell
activation.
The specificity and the effectiveness of the control exerted
by S1P on lymphocyte trafficking are determined by the local
concentration of S1P. Typically, concentration gradients of S1P
ranging from 3 to 30 nM induce chemotaxis of thymocytes, T
and B lymphocytes, and presumably thymocyte emigration and
lymphocyte movement from lymph nodes back into efferent
lymph and then to the blood [108]. Developmental upregulation
of S1P1 expression in the thymus has been reported [105,109].
Expression of S1P1 is first observed on CD4
+CD8+ thymocytes,
reaching the highest level of expression on single positive cells,
which become ready to exit the thymus [109]. Indeed, lym-
phocyte-specific S1P1 knockout mice display medullary hyper-
plasia of otherwise normal thymocytes [110]. Interactions
between chemokine signaling and S1P receptor signaling are
still undefined, but may be of importance for driving T cells into
peripheral lymph nodes as splenic and lymph node T cells have
distinct requirements for, and responses to both chemokines and
S1P [111].
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various models of graft versus host disease and autoimmunity
and appears to be beneficial for treatment of multiple sclerosis
[112]. FTY720 is a sphingosine analog, which after phosphor-
ylation in vivo by SphK2 regulates lymphocyte trafficking
through its interaction with S1P1 [112,113]. FTY720-phosphate
is a true agonist with nanomolar potency for all of the S1P
receptors, except S1P2 [102]. SphK1 null mice, but not SphK2
knockouts, become lymphopenic upon administration of
FYT720 [110,114], substantiating previous results showing
that FTY720 was a much better substrate for SphK2 than SphK1
[18]. The recent finding that FTY720 can also severely hamper
migration of dendritic cells to the lymph nodes suggests addi-
tional mechanisms underlying the immunosuppressive effects of
this sphingosine analog [115].
7.6. S1P and asthma
Mast cells play pivotal roles in immediate-type and inflam-
matory allergic reactions that can result in asthma a disease of
chronic airway inflammation. Cross-linking of the high-affinity
receptor for IgE (FcepsilonRI) on these cells leads to degra-
nulation and the release of histamine and other preformed
mediators, chemokines and cytokines, as well as eicosanoids
(leukotrienes and prostaglandins), and S1P [116]. It has
previously been suggested that the decisive balance between
sphingosine and S1P determines the allergic responsiveness of
mast cells [117].Whereas sphingosine inhibits antigen-mediated
leukotriene synthesis and cytokine production by preventing
activation of ERK1/2, S1P activates it, stimulating degranula-
tion and cytokine production [117]. S1P formed after antigenic
stimulation is able to rapidly bind and activate its receptors S1P1
and S1P2 present on mast cells [24,118]. S1P1 induces
cytoskeletal rearrangements, leading to the movement of mast
cells towards an antigen gradient, whereas transactivation of
S1P2 enhances the degranulation response. Thus, we have
suggested that low antigen concentrations can attract mast cells
to the site of action via S1P1, and, as mast cells approach higher
concentrations of antigen, a shift in the expression of S1P
receptors (enhanced S1P2 expression) resolves migration while
promoting degranulation, a process known to require a stronger
stimulus [24].
SphK1 translocates to the plasma membrane within minutes
of FcεpsilonRI clustering [24,119]. SphK1 interacts with Lyn
and Fyn, FcεpsilonRI proximal kinases that initiate the
signaling events following cross-linking of this receptor [48].
Recently, a cooperative role between Fyn and Lyn kinases in the
activation of both SphK1 and SphK2 has been demonstrated,
which contributes to mast cell responses [120]. Intracellular S1P
is also thought to mobilize calcium from intracellular stores
[27,119], independently of phospholipase C (PLC) activation
and inositol 1,4,5-trisphosphate (InsP3) generation, and this is
necessary for mast cell degranulation.
Because expression of MCP-1, MIP1-α, MIP1-β, MIP2
(belonging to the CC-chemokine family), and MIF, all
important modulators of monocyte and eosinophil recruitment
and inflammation, were significantly increased by S1P in mastcells [24], it is also possible that secretion of S1P by mast cells
can also promote inflammation by activating and recruiting
other immune cells involved in allergic and inflammatory
responses. S1P also profoundly affects endothelial cell function
and promotes adhesion molecule expression in endothelial cells
[49,92], induces contraction and proliferation of smooth muscle
cells and stimulates IL-6 production in airway smooth muscle
cells [121], and shifts maturing dendritic cell-induced polariza-
tion of T cells into a Th2 phenotype [122]. Because its levels are
elevated in the broncholavage fluid of asthmatic individuals
after Ag challenge, secretion of S1P by mast cells is of great
relevance in inflammatory responses and asthma [24,121].
7.7. S1P and the reproductive system
While not yet extensively studied, evidence has begun to
accumulate that S1P also has important functions in male
and female reproductive systems. S1P1 receptors are
constitutively expressed in the seminiferous tubules of the
testes but not on primary spermatocytes or Sertoli cells
[123]. S1P can provide protection against radiation-induced
male germ cell loss, evoking a role for S1P in the survival of
male germ cells [124]. Similarly, S1P administration prevents
oocyte apoptosis and infertility subsequent to cytotoxic
chemotherapy treatment in females [125]. Such studies
open new avenues of clinical relevance for the control of
ovarian germ cell dynamics and potential management of
ovarian failure in women, as well as for preservation of
ovarian function in female cancer patients.
7.8. S1P and the central nervous system
In vitro studies as well as gene knockouts have begun to
elucidate important functions for S1P (and ceramide) in neurons
and in glial cells. In neuronal cultures, S1P acts through two
S1PRs, S1P2 and S1P5, to regulate neurite retraction and soma
rounding [126]. In the CNS, S1P receptor expression is regulated
throughout development, with a specific distribution profile
within the brain [126]. S1P5 expressed by oligodendrocytes
might play a role in normal myelination and in demyelinating
diseases, such as multiple sclerosis, as its expression is restricted
to oligodendrocytes throughout development from immature
stages to myelin-forming cells [127]. Studies from Sato-
Bigbee's lab demonstrated that neurotrophin (NT)-3 is a potent
activator of the transcription factor CREB [128,129] and more
recently, that CREB phosphorylation is stimulated by S1P in
oligodendrocyte progenitors, demonstrating crosstalk between
NT-3 and S1P signaling [130]. It has been difficult to ascertain
the importance of S1P production in the brain since neither
SphK1 nor SphK2 knockout mice have any obvious CNS
phenotypes, likely due to complementation since the S1P levels
are not seriously compromised and knockout of both SphKs
results in a severe brain developmental defect [86]. The SphK1/
SphK2 double knockout is embryonically lethal and embryos
have no S1P and exhibit severely disturbed neurogenesis,
including neural tube closure, and angiogenesis. A dramatic
increase in apoptosis and a decrease in mitosis were seen in the
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showed severe defects in neurogenesis [86]. The neural defects
of increased cell death and decreased proliferation in the neuro-
epithelium of almost all brain regions, particularly in the telen-
cephalon, that correlated with thinning of the neuroepithelial
layer, was much more severe in the double SphK knockout
embryos compared to S1P1 knockout embryos. Moreover, in
contrast to SphK1/SphK2 null embryos, neural tube defects
were not observed in S1P1 null embryos. These results suggest
that S1P may also have intracellular function to regulate cell
survival independent of S1P1. Alternatively, other S1P receptors
might be important as it is known that functional S1P receptors
are expressed in the embryonic brain in areas where active
neurogenesis takes place [131]. Of note, S1P can be secreted by
astroglial cells [132] and by cells from the cerebellum [133] and
thus might function in an autocrine and/or paracrine manner
within the CNS.
Acknowledgements
This work was supported by National Institutes of Health
grants GM43880, CA61774, and AI50094 to Sarah Spiegel and
in part, by the Intramural Program of the NIMH, NIH. We apo-
logize to those colleagues whose work could not be cited due to
space limitations.
References
[1] A.H. Merrill Jr., J. Biol. Chem. 277 (2002) 25843–25846.
[2] R. Kolesnick, Y.A. Hannun, Trends Biochem. Sci. 24 (1999) 224–225.
[3] K. Hanada, K. Kumagai, S. Yasuda, Y. Miura, M. Kawano, M. Fukasawa,
M. Nishijima, Nature 426 (2003) 803–809.
[4] G. vanMeer, J.C. Holthuis, Biochim. Biophys. Acta 1486 (2000) 145–170.
[5] S. Spiegel, S. Milstien, Nature Rev. Mol. Cell. Biol. 4 (2003) 397–407.
[6] M.M. Nagiec, M. Skrzypek, E.E. Nagiec, R.L. Lester, R.C. Dickson,
J. Biol. Chem. 273 (1998) 19437–19442.
[7] N.C. Hait, K. Fujita, R.L. Lester, R.C. Dickson, FEBS Lett. 532 (2002)
97–102.
[8] M. Maceyka, H. Sankala, N.C. Hait, H. Le Stunff, H. Liu, R. Toman, C.
Collier, M. Zhang, L. Satin, A.H. Merrill Jr., S. Milstien, S. Spiegel,
J. Biol. Chem. 280 (2005) 37118–37129.
[9] H. Liu, R.E. Toman, S. Goparaju, M. Maceyka, V.E. Nava, H. Sankala,
S.G. Payne, M. Bektas, I. Ishii, J. Chun, S. Milstien, S. Spiegel, J. Biol.
Chem. 278 (2003) 40330–40336.
[10] K. Funato, R. Lombardi, B. Vallée, H. Riezman, J. Biol. Chem. 278
(2003) 7325–7334.
[11] A.H. Futerman, H. Riezman, Trends Cell Biol. 15 (2005) 312–318.
[12] T. Kohama, A. Olivera, L. Edsall, M.M. Nagiec, R. Dickson, S. Spiegel,
J. Biol. Chem. 273 (1998) 23722–23728.
[13] L.C. Edsall, J.R. Van Brocklyn, O. Cuvillier, B. Kleuser, S. Spiegel,
Biochemistry 37 (1998) 12892–12898.
[14] K. Kono, M. Tanaka, Y. Ono, T. Hosoya, T. Ogita, T. Kohama, J. Antibiot.
(Tokyo) 54 (2001) 415–420.
[15] K.J. French, R.S. Schrecengost, B.D. Lee, Y. Zhuang, S.N. Smith, J.L.
Eberly, J.K. Yun, C.D. Smith, Cancer Res. 63 (2003) 5962–5969.
[16] H. Liu, M. Sugiura, V.E. Nava, L.C. Edsall, K. Kono, S. Poulton, S.
Milstien, T. Kohama, S. Spiegel, J. Biol. Chem. 275 (2000) 19513–19520.
[17] S.M. Pitson, P.A. Moretti, J.R. Zebol, R. Zareie, C.K. Derian, A.L.
Darrow, J. Qi, R.J. D'Andrea, C.J. Bagley, M.A. Vadas, B.W.Wattenberg,
J. Biol. Chem. 277 (2002) 49545–49553.
[18] S.W. Paugh, S.G. Payne, S.E. Barbour, S. Milstien, S. Spiegel, FEBS
Lett. 554 (2003) 189–193.[19] A. Billich, F. Bornancin, P. Devay, D. Mechtcheriakova, N. Urtz, T.
Baumruker, J. Biol. Chem. 278 (2003) 47408–47415.
[20] T. Sanchez, T. Estrada-Hernandez, J.H. Paik, M.T. Wu, K. Venkataraman,
V. Brinkmann, K. Claffey, T. Hla, J. Biol. Chem. 278 (2003)
47281–47290.
[21] N. Igarashi, T. Okada, S. Hayashi, T. Fujita, S. Jahangeer, S.I. Nakamura,
J. Biol. Chem. 278 (2003) 46832–46839.
[22] N.C. Hait, S. Sarkar, H. Le Stunff, A. Mikami, M. Maceyka, S. Milstien,
S. Spiegel, J. Biol. Chem. 280 (2005) 29462–29469.
[23] S.K. Goparaju, P.S. Jolly, K.R. Watterson, M. Bektas, S. Alvarez, S.
Sarkar, L. Mel, I. Ishii, J. Chun, S. Milstien, S. Spiegel, Mol. Cell. Biol.
25 (2005) 4237–4249.
[24] P.S. Jolly, M. Bektas, A. Olivera, C. Gonzalez-Espinosa, R.L. Proia, J.
Rivera, S. Milstien, S. Spiegel, J. Exp. Med. 199 (2004) 959–970.
[25] T. Blom, J.P. Slotte, S.M. Pitson, K. Tornquist, Cell Signalling 17 (2005)
827–836.
[26] D.M. zu Heringdorf, M.E. Vincent, M. Lipinski, K. Danneberg, U.
Stropp, D.A. Wang, G. Tigyi, K.H. Jakobs, Cell Signalling 15 (2003)
677–687.
[27] O.H. Choi, J.-H. Kim, J.-P. Kinet, Nature 380 (1996) 634–636.
[28] V.S. Limaye, X. Li, C. Hahn, P. Xia, M.C. Berndt, M.A. Vadas, J.R.
Gamble, Blood 105 (2005) 3169–3177.
[29] P. Xia, L. Wang, P.A. Moretti, N. Albanese, F. Chai, S.M. Pitson, R.J.
D'Andrea, J.R. Gamble, M.A. Vadas, J. Biol. Chem. 277 (2002)
7996–8003.
[30] C. De Palma, E. Meacci, C. Perrotta, P. Bruni, E. Clementi, Arterioscler.,
Thromb., Vasc. Biol. 26 (2006) 99–105.
[31] X. Shu, W. Wu, R.D. Mosteller, D. Broek, Mol. Cell. Biol. 22 (2002)
7758–7768.
[32] S. Sarkar, M. Maceyka, N.C. Hait, S.W. Paugh, H. Sankala, S. Milstien,
S. Spiegel, FEBS Lett. 579 (2005) 5313–5317.
[33] A.J. Melendez, F.B. Ibrahim, J. Immunol. 173 (2004) 1596–1603.
[34] S. Iwaki, A. Kihara, T. Sano, Y. Igarashi, J. Biol. Chem. 280 (2005)
6520–6527.
[35] A. Kihara, F. Kurotsu, T. Sano, S. Iwaki, Y. Igarashi, Mol. Cell. Biol. 25
(2005) 9189–9197.
[36] K.R. Johnson, K.P. Becker, M.M. Facchinetti, Y.A. Hannun, L.M. Obeid,
J. Biol. Chem. 277 (2002) 35257–35262.
[37] S.M. Pitson, P.A. Moretti, J.R. Zebol, H.E. Lynn, P. Xia, M.A. Vadas,
B.W. Wattenberg, EMBO J. 22 (2003) 5491–5500.
[38] P. Xia, M.A. Vadas, K.A. Rye, P.J. Barter, J.R. Gamble, J. Biol. Chem.
274 (1999) 33143–33147.
[39] S.M. Pitson, P.A. Moretti, J.R. Zebol, P. Xia, J.R. Gamble, M.A.
Vadas, R.J. D', B.W. Wattenberg, J. Biol. Chem. 275 (2000)
33945–33950.
[40] A. Olivera, J. Rosenthal, S. Spiegel, J. Cell. Biochem. 60 (1996)
529–537.
[41] C. Delon, M. Manifava, E. Wood, D. Thompson, S. Krugmann, S. Pyne,
N.T. Ktistakis, J. Biol. Chem. 279 (2004) 44763–44774.
[42] R.V. Stahelin, J.H. Hwang, J.H. Kim, Z.Y. Park, K.R. Johnson, L.M.
Obeid, W. Cho, J. Biol. Chem. 280 (2005) 43030–43038.
[43] S. Hayashi, T. Okada, N. Igarashi, T. Fujita, S. Jahangeer, S. Nakamura,
J. Biol. Chem. 277 (2002) 33319–33324.
[44] E. Lacana, M. Maceyka, S. Milstien, S. Spiegel, J. Biol. Chem. 277
(2002) 32947–32953.
[45] M. Maceyka, V.E. Nava, S. Milstien, S. Spiegel, FEBS Lett. 568 (2004)
30–34.
[46] Y. Fukuda, Y. Aoyama, A. Wada, Y. Igarashi, Biochim. Biophys. Acta
1636 (2004) 12–21.
[47] T. Fujita, T. Okada, S. Hayashi, S. Jahangeer, N. Miwa, S. Nakamura,
Biochem. J. 382 (2004) 717–723.
[48] N. Urtz, A. Olivera, E. Bofill-Cardona, R. Csonga, A. Billich, D.
Mechtcheriakova, F. Bornancin, M. Woisetschlager, J. Rivera, T.
Baumruker, Mol. Cell. Biol. 24 (2004) 8765–8777.
[49] P. Xia, J.R. Gamble, K.A. Rye, L. Wang, C.S.T. Hii, P. Cockerill, Y.
Khew-Goodall, A.G. Bert, P.J. Barter, M.A. Vadas, Proc. Natl. Acad. Sci.
U.S.A. 95 (1998) 14196–14201.
[50] R.A. Rius, L.C. Edsall, S. Spiegel, FEBS Lett. 417 (1997) 173–176.
2025N.C. Hait et al. / Biochimica et Biophysica Acta 1758 (2006) 2016–2026[51] B.M. Buehrer, E.S. Bardes, R.M. Bell, Biochim. Biophys. Acta 1303
(1996) 233–242.
[52] B. Kleuser, O. Cuvillier, S. Spiegel, Cancer Res. 58 (1998) 1817–1824.
[53] B.J. Pettus, J. Bielawski, A.M. Porcelli, D.L. Reames, K.R. Johnson, J.
Morrow, C.E. Chalfant, L.M. Obeid, Y.A. Hannun, FASEB J. 17 (2003)
1411–1421.
[54] T. Yoshimoto, M. Furuhata, S. Kamiya, M. Hisada, H. Miyaji, Y.
Magami, K. Yamamoto, H. Fujiwara, J. Mizuguchi, J. Immunol. 171
(2003) 1352–1359.
[55] A. Olivera, T. Kohama, L.C. Edsall, V. Nava, O. Cuvillier, S. Poulton, S.
Spiegel, J. Cell Biol. 147 (1999) 545–558.
[56] P. Xia, J.R. Gamble, L. Wang, S.M. Pitson, P.A. Moretti, B.W.
Wattenberg, R.J. D'Andrea, M.A. Vadas, Curr. Biol. 10 (2000)
1527–1530.
[57] V.E. Nava, J.P. Hobson, S. Murthy, S. Milstien, S. Spiegel, Exp. Cell Res.
281 (2002) 115–127.
[58] O.A. Sukocheva, L. Wang, N. Albanese, S.M. Pitson, M.A. Vadas, P. Xia,
Mol. Endocrinol. 17 (2003) 2002–2012.
[59] S.M. Pitson, P. Xia, T.M. Leclercq, P.A. Moretti, J.R. Zebol, H.E. Lynn,
B.W. Wattenberg, M.A. Vadas, J. Exp. Med. 201 (2005) 49–54.
[60] K.R. Johnson, K.Y. Johnson, H.G. Crellin, B. Ogretmen, A.M. Boylan,
R.A. Harley, L.M. Obeid, J. Histochem. Cytochem. 53 (2005)
1159–1166.
[61] W. Wu, X. Shu, H. Hovsepyan, R.D. Mosteller, D. Broek, Oncogene 22
(2003) 3361–3370.
[62] J.R. VanBrocklyn, C.A. Jackson, D.K. Pearl, M.S. Kotur, P.J. Snyder,
T.W. Prior, J. Neuropathol. Exp. Neurol. 64 (2005) 695–705.
[63] T.A. Taha, K. Kitatani, J. Bielawski, W. Cho, Y.A. Hannun, L.M. Obeid,
J. Biol. Chem. 280 (2005) 17196–17202.
[64] O. Cuvillier, V.E. Nava, S.K. Murthy, L.C. Edsall, T. Levade, S. Milstien,
S. Spiegel, Cell Death Differ. 8 (2001) 162–171.
[65] D.C. Huang, A. Strasser, Cell 103 (2000) 839–842.
[66] M.J. Berridge, P. Lipp, M.D. Bootman, Nat. Rev., Mol. Cell Biol. 1
(2000) 11–21.
[67] P. Pinton, D. Ferrari, E. Rapizzi, F.D. Di Virgilio, T. Pozzan, R. Rizzuto,
EMBO J. 20 (2001) 2690–2701.
[68] L. Scorrano, S.A. Oakes, J.T. Opferman, E.H. Cheng, M.D. Sorcinelli, T.
Pozzan, S.J. Korsmeyer, Science 300 (2003) 135–139.
[69] L.K. Nutt, J. Chandra, A. Pataer, B. Fang, J.A. Roth, S.G. Swisher,
R.G. O'Neil, D.J. McConkey, J. Biol. Chem. 277 (2002)
20301–20308.
[70] C.J. Birchwood, J.D. Saba, R.C. Dickson, K.W. Cunningham, J. Biol.
Chem. 276 (2001) 11712–11718.
[71] C.K. Ng, K. Carr, M.R. McAinsh, B. Powell, A.M. Hetherington, Nature
410 (2001) 596–599.
[72] G. Li, H. Alexander, N. Schneider, S. Alexander, Microbiology 146
(2000) 2127–2219.
[73] G. Li, C. Foote, S. Alexander, H. Alexander, Development 128 (2001)
3473–3483.
[74] J. Min, D. Traynor, A.L. Stegner, L. Zhang, M.H. Hanigan, H. Alexander,
S. Alexander, Eukaryot. Cell. 4 (2005) 178–189.
[75] B. Ogretmen, Y.A. Hannun, Nat. Rev., Cancer 4 (2004) 604–616.
[76] Y. Osawa, H. Uchinami, J. Bielawski, R.F. Schwabe, Y.A. Hannun, D.A.
Brenner, J. Biol. Chem. 280 (2005) 27879–27887.
[77] S.M. Mandala, R. Thornton, I. Galve-Roperh, S. Poulton, C. Peterson, A.
Olivera, J. Bergstrom, M.B. Kurtz, S. Spiegel, Proc. Natl. Acad. Sci.
U.S.A. 97 (2000) 7859–7864.
[78] H. Le Stunff, I. Galve-Roperh, C. Peterson, S. Milstien, S. Spiegel, J. Cell
Biol. 158 (2002) 1039–1049.
[79] K.R. Johnson, K.Y. Johnson, K.P. Becker, C. Mao, L.M. Obeid, J. Biol.
Chem. 278 (2003) 34541–34547.
[80] J.R. Van Brocklyn, N. Young, R. Roof, Cancer Lett. 199 (2003)
53–60.
[81] F. Liu, A.D. Verin, P. Wang, R. Day, R.P. Wersto, F.J. Chrest, D.K.
English, J.G. Garcia, Am. J. Respir. Cell Mol. Biol. 24 (2001)
711–719.
[82] M.J. Lee, S. Thangada, K.P. Claffey, N. Ancellin, C.H. Liu, M. Kluk, M.
Volpi, R.I. Sha'afi, T. Hla, Cell 99 (1999) 301–312.[83] T. Licht, L. Tsirulnikov, H. Reuveni, T. Yarnitzky, S.A. Ben-Sasson,
Blood 102 (2003) 2099–2107.
[84] Y. Liu, R. Wada, T. Yamashita, Y. Mi, C.X. Deng, J.P. Hobson, H.M.
Rosenfeldt, V.E. Nava, S.S. Chae, M.J. Lee, C.H. Liu, T. Hla, S. Spiegel,
R.L. Proia, J. Clin. Invest. 106 (2000) 951–961.
[85] S.S. Chae, J.H. Paik, H. Furneaux, T. Hla, J. Clin. Invest. 114 (2004)
1082–1089.
[86] K. Mizugishi, T. Yamashita, A. Olivera, G.F. Miller, S. Spiegel, R.L.
Proia, Mol. Cell. Biol. 25 (2005) 11113–11121.
[87] N. Murata, K. Sato, J. Kon, H. Tomura, M. Yanagita, A. Kuwabara, M.
Ui, F. Okajima, Biochem. J. 352 (2000) 809–815.
[88] Y. Yatomi, Y. Igarashi, L. Yang, N. Hisano, R. Qi, N. Asazuma, K. Satoh,
Y. Ozaki, S. Kume, J. Biochem. 121 (1997) 969–973.
[89] L. Yang, Y. Yatomi, K. Satoh, Y. Igarashi, Y. Ozaki, J. Biochem. (Tokyo)
126 (1999) 84–89.
[90] T. Kimura, K. Sato, A. Kuwabara, H. Tomura, M. Ishiwara, I. Kobayashi,
M. Ui, F. Okajima, J. Biol. Chem. 276 (2001) 31780–31785.
[91] J.H. Paik, S. Chae, M.J. Lee, S. Thangada, T. Hla, J. Biol. Chem. 276
(2001) 11830–11837.
[92] J.G. Garcia, F. Liu, A.D. Verin, A. Birukova, M.A. Dechert, W.T.
Gerthoffer, J.R. Bamberg, D. English, J. Clin. Invest. 108 (2001)
689–701.
[93] F. Okajima, Biochim. Biophys. Acta 1582 (2002) 132–137.
[94] W. Siess, Biochim. Biophys. Acta 1582 (2002) 204–215.
[95] G. Seitz, A.M. Boehmler, L. Kanz, R. Mohle, Ann. N. Y. Acad. Sci. 1044
(2005) 84–89.
[96] D.T. Bolick, S. Srinivasan, K.W. Kim, M.E. Hatley, J.J. Clemens, A.
Whetzel, N. Ferger, T.L. Macdonald, M.D. Davis, P.S. Tsao, K.R.
Lynch, C.C. Hedrick, Arterioscler., Thromb., Vasc. Biol. 25 (2005)
976–981.
[97] L.B. Ware, M.A. Matthay, N. Engl. J. Med. 342 (2000) 1334–1349.
[98] A.C. MacKinnon, A. Buckley, E.R. Chilvers, A.G. Rossi, C. Haslett, T.
Sethi, J. Immunol. 169 (2002) 6394–6400.
[99] K. Itagaki, C.J. Hauser, J. Biol. Chem. 278 (2003) 27540–27547.
[100] C. Lee, D.Z. Xu, E. Feketeova, K.B. Kannan, J.K. Yun, E.A. Deitch,
Z. Fekete, D.H. Livingston, C.J. Hauser, J. Trauma 57 (2004)
955–960.
[101] X. Peng, P.M. Hassoun, S. Sammani, B.J. McVerry, M.J. Burne, H. Rabb,
D. Pearse, R.M. Tuder, J.G. Garcia, Am. J. Respir. Crit. Care Med. 169
(2004) 1245–1251.
[102] V. Brinkmann, M.D. Davis, C.E. Heise, R. Albert, S. Cottens, R.
Hof, C. Bruns, E. Prieschl, T. Baumruker, P. Hiestand, C.A.
Foster, M. Zollinger, K.R. Lynch, J. Biol. Chem. 277 (2002)
21453–21457.
[103] Y. Gon, M.R. Wood, W.B. Kiosses, E. Jo, M.G. Sanna, J. Chun, H.
Rosen, Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 9270–9275.
[104] L.P. Vlasenko, A.J. Melendez, J. Immunol. 174 (2005) 6456–6461.
[105] E.J. Goetzl, H. Rosen, J. Clin. Invest. 114 (2004) 1531–1537.
[106] Y. Zheng, J.K. Voice, Y. Kong, E.J. Goetzl, FASEB J. 14 (2000)
2387–2389.
[107] M. Graeler, E.J. Goetzl, FASEB J. 16 (2002) 1874–1878.
[108] E.J. Goetzl, M.H. Graler, J. Leukocyte Biol. 76 (2004) 30–35.
[109] M. Matloubian, C.G. Lo, G. Cinamon, M.J. Lesneski, Y. Xu, V.
Brinkmann, M.L. Allende, R.L. Proia, J.G. Cyster, Nature 427 (2004)
355–360.
[110] M.L. Allende, J.L. Dreier, S. Mandala, R.L. Proia, J. Biol. Chem. 279
(2004) 15396–15401.
[111] A.C. Yopp, J.C. Ochando, M. Mao, L. Ledgerwood, Y. Ding, J.S.
Bromberg, J. Immunol. 175 (2005) 2913–2924.
[112] V. Brinkmann, K.R. Lynch, Curr. Opin. Immunol. 14 (2002) 569–575.
[113] M. Matsuura, T. Imayoshi, K. Chiba, T. Okumoto, Inflamm. Res. 49
(2000) 404–410.
[114] Y. Kharel, S. Lee, A.H. Snyder, L. Sheasley-O'neill S, M.A. Morris, Y.
Setiady, R. Zhu, M.A. Zigler, T.L. Burcin, K. Ley, K.S. Tung, V.H.
Engelhard, T.L. Macdonald, K.R. Lynch, J. Biol. Chem. 280 (2005)
36865–36872.
[115] N. Czeloth, G. Bernhardt, F. Hofmann, H. Genth, R. Forster, J. Immunol.
175 (2005) 2960–2967.
2026 N.C. Hait et al. / Biochimica et Biophysica Acta 1758 (2006) 2016–2026[116] J. Rivera, A.M. Gilfillan, J. Allergy Clin. Immunol. 117 (2006)
1214–1225.
[117] E.E. Prieschl, R. Csonga, V. Novotny, G.E. Kikuchi, T. Baumruker,
J. Exp. Med. 190 (1999) 1–8.
[118] P.S. Jolly, M. Bektas, K.R. Watterson, H. Sankala, S.G. Payne, S.
Milstien, S. Spiegel, Blood 105 (2005) 4736–4742.
[119] A.J. Melendez, A.K. Khaw, J. Biol. Chem. 277 (2002) 17255–17262.
[120] A. Olivera, N. Urtz, K. Mizugishi, Y. Yamashita, A.M. Gilfillan, Y.
Furumoto, H. Gu, R.L. Proia, T. Baumruker, J. Rivera, J. Biol. Chem. 281
(2006) 2515–2525.
[121] A.J. Ammit, A.T. Hastie, L.C. Edsall, R.K. Hoffman, Y. Amrani, V.P.
Krymskaya, S.A. Kane, S.P. Peters, R.B. Penn, S. Spiegel, R.A. Panettieri
Jr., FASEB J. 15 (2001) 1212–1214.
[122] M. Idzko, E. Panther, S. Corinti, A. Morelli, D. Ferrari, Y. Herouy,
S. Dichmann, M. Mockenhaupt, P. Gebicke-Haerter, F. Di Virgilio,
G. Girolomoni, J. Norgauerz, FASEB J. 16 (2002) 625–627.
[123] S.S. Chae, R.L. Proia, T. Hla, Prostaglandins Other Lipid Mediat 73
(2004) 141–150.
[124] L. Suomalainen, V. Pentikainen, L. Dunkel, Am. J. Pathol. 166 (2005)
773–781.[125] F. Paris, G.I. Perez, Z. Fuks, A. Haimovitz-Friedman, H. Nguyen, M.
Bose, A. Ilagan, P.A. Hunt, W.F. Morgan, J.L. Tilly, R. Kolesnick, Nat.
Med. 8 (2002) 901–902.
[126] R.E. Toman, V. Movsesyan, S.K. Murthy, S. Milstien, S. Spiegel, A.I.
Faden, J. Neurosci. Res. 68 (2002) 323–330.
[127] C. Jaillard, S. Harrison, B. Stankoff, M.S. Aigrot, A.R. Calver, G. Duddy,
F.S. Walsh, M.N. Pangalos, N. Arimura, K. Kaibuchi, B. Zalc, C.
Lubetzki, J. Neurosci. 25 (2005) 1459–1469.
[128] J.R. Johnson, A.K. Chu, C. Sato-Bigbee, J. Neurochem. 74 (2000)
1409–1417.
[129] H.S. Saini, K.M. Gorse, L.M. Boxer, C. Sato-Bigbee, J. Neurochem. 89
(2004) 951–961.
[130] H.S. Saini, R.P. Coelho, S.K. Goparaju, P.S. Jolly, M. Maceyka, S.
Spiegel, C. Sato-Bigbee, J. Neurochem. 95 (2005) 1298–1310.
[131] J. Harada, M. Foley, M.A. Moskowitz, C. Waeber, J. Neurochem. 88
(2004) 1026–1039.
[132] L.C. Edsall, O. Cuvillier, S. Twitty, S. Spiegel, S. Milstien, J. Neurochem.
76 (2001) 1573–1584.
[133] V. Anelli, R. Bassi, G. Tettamanti, P. Viani, L. Riboni, J. Neurochem. 92
(2005) 1204–1215.
